Oral Janus Kinase Inhibitors in Pediatric Vitiligo: A Real-World Retrospective Cohort Study

Supplementary Table 1 shows the treatment duration for disease progression control in different types of patients. Supplementary Table 2 shows the adverse reactions of the patients. Supplementary Figure 1 shows the percentage of improvement in facial VASI scores over treatment time for all patients. Supplementary Figure 2 shows the percentage of improvement in trunk VASI scores over treatment time for all patients. Supplementary Figures 3, 4, and 5 contain before-and-after treatment photos of some patients.